Nilsine Partners’s Novo Nordisk NVO Stock Holding History

Nilsine Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.33M	Sell	69,503 -836	-1%	-$35.9K	0.23%	104
2026 Q1	$2.9M	Sell	70,339 -3,312	-4%	-$157K	0.23%	103
2025 Q4	$3.75M	Buy	73,651 +97	+0.1%	+$4.96K	0.32%	68
2025 Q3	$4.08M	Buy	73,554 +637	+0.9%	+$37.3K	0.37%	58
2025 Q2	$5.03M	Sell	72,917 -926	-1%	-$63K	0.51%	41
2025 Q1	$5.13M	Buy	73,843 +3,102	+4%	+$256K	0.56%	37
2024 Q4	$6.09M	Buy	70,741 +1,768	+3%	+$191K	0.65%	30
2024 Q3	$8.21M	Sell	68,973 -338	-0.5%	-$45.1K	1.06%	18
2024 Q2	$9.89M	Sell	69,311 -1,185	-2%	-$157K	1.33%	16
2024 Q1	$9.05M	Sell	70,496 -930	-1%	-$111K	1.24%	17
2023 Q4	$7.39M	Sell	71,426 -1,860	-3%	-$184K	1.14%	18
2023 Q3	$6.66M	Buy	73,286 +968	+1%	+$85.3K	1.01%	22
2023 Q2	$5.85M	Buy	72,318 +1,668	+2%	+$136K	0.86%	25
2023 Q1	$5.62M	Buy	+70,650	New	+$5.01M	0.88%	24

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

OFA

Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Nilsine Partners's NVO Position: Q2 2026 in Review

Nilsine Partners reduced its Novo Nordisk (NVO) stake by 1.2% in Q2 2026, selling an estimated $35.9K and leaving 69,503 shares worth $3.33M. The position accounts for 0.23% of the portfolio, ranked #104.

Nilsine Partners first reported a position in NVO in Q1 2023 and has held it in 14 quarters since. The position peaked at $9.89M in Q2 2024. 387 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Nilsine Partners held 69,503 shares of Novo Nordisk worth $3.33M as of Q2 2026.
Nilsine Partners sold 836 Novo Nordisk shares in Q2 2026, an estimated $35.9K.
Novo Nordisk made up 0.23% of Nilsine Partners's portfolio in Q2 2026, its #104 holding.
Nilsine Partners first reported a position in Novo Nordisk in Q1 2023 and has held it in 14 quarters since.
Nilsine Partners's Novo Nordisk position peaked at $9.89M in Q2 2024.
387 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.